One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry

BACKGROUND: Registry studies provide a valuable source of comparative safety data for tumor necrosis factor inhibitors (TNFi) used in rheumatoid arthritis (RA), but they are subject to channeling bias. Comparing safety outcomes without accounting for channeling bias can lead to inaccurate comparison...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrold, Leslie R., Litman, Heather J., Saunders, Katherine C., Dandreo, Kimberly J., Gershenson, Bernice, Greenberg, Jeffrey D., Low, Robert, Stark, Jeffrey, Suruki, Robert, Jaganathan, Srihari, Kremer, Joel M., Yassine, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795286/
https://www.ncbi.nlm.nih.gov/pubmed/29329557
http://dx.doi.org/10.1186/s13075-017-1496-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795286/
https://www.ncbi.nlm.nih.gov/pubmed/29329557
http://dx.doi.org/10.1186/s13075-017-1496-5

Ejemplares similares